DURECT -29% AH as FDA denies approval for Posidur


DURECT (DRRX) -29.2% AH as the FDA fails to approve the company's Posidur investigational drug for post-operative pain relief.

The FDA says the new drug application did not demonstrate that Posidur is safe, and additional clinical safety studies need to be conducted.

From other sites
Comments (1)
  • billy meeker
    , contributor
    Comments (5) | Send Message
     
    I have gone to college for 49 years studying subjects that interest me, from Human behavior, to math, I was wondering about the speed of light? how did they figure it out? Or the distance from the moon we are or sun; I noticed in the "method". & a sketch of a prism with a lot of ides beyond Newton in 200 BCE;
    13 Feb 2014, 09:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs